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Abstract Osteoprotegerin (OPG) is
a protein that inhibits of osteoclas-
togenesis. The aim this study was
to evaluate the response of serum
OPG levels to neridronate treatment
in patients with Paget’s disease of
bone resistant to previous therapy.
Nine patients (4 men) affected by
active Paget’s disease of bone (6
polyostotic, 3 monostotic) not
responsive to clodronate were stud-
ied. Serum OPG, osteocalcin, total
and bone isoenzyme of alkaline
phosphatase (AP and BAP, respec-
tively), and urinary deoxypyridino-
line (DPD) were measured before
and 5 months after neridronate
treatment (100 mg/day, i.v. for two
days). A scintigraphic activity
index (SAI) was also calculated
before treatment. Mean baseline
OPG levels were within normal val-
ues and were not significantly dif-
ferent 5 months after neridronate
treatment. In contrast, there were
significant reductions in AP
(41.9%, p<0.02) and BAP (38.8%,
p<0.04). Serum OPG levels corre-
lated with DPD (r=0.925) and SAI
(r=0.689). Although OPG is an
important regulator of bone metab-
olism, in our series of already treat-
ed patients it was not a sensitive
marker for diagnosing Paget’s dis-
ease and for monitoring the
response to pharmacological treat-
ment, whereas AP and BAP con-
firmed their clinical usefulness.
This preliminary study requires
confirmation by a study with a larg-
er population.
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whose main function is to decrease bone resorption by
inhibiting osteoclast activity [2]. A recent bisphosphonate
used for this purpose is neridronate (6-amino-1-hydroxy-
hexilidene-1,1-bisphosphonate monosodium), a third-gen-
eration aminobisphosphonate, which is well tolerated
even at high doses [3].
To monitor the effectiveness of these drugs in follow-
up, usual biochemical parameters of bone formation and
resorption are widely assessed. Recently, some new mem-
bers of the tumor necrosis factor receptor family have
been identified as regulators of osteoclastogenesis and
Introduction
Paget’s disease of bone is a local disorder of bone remod-
eling characterized by an excessive increase in the meta-
bolic activity of bone. An acceleration of osteoclast-medi-
ated bone resorption, followed by an increase in osteo-
blastic activity, leads to replacement of normal bone by an
abnormal and weakened bone structure that is prone to
pain, deformity and fracture [1]. The present first-choice
treatment for Paget’s disease of bone are bisphosphonates,
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bone resorption: osteoprotegerin (OPG) and its ligand
(RANKL), the receptor activator of nuclear factor-Kappa
B ligand. OPG binds to RANKL, an essential cytokine
required for osteoclastogenesis, and inhibits osteoclast
differentiation, suppresses activation of mature osteo-
clasts, and drives them into apoptosis [4, 5].
Recently, Alvarez et al. [6] described high serum levels
of OPG in patients with Paget’s disease of bone. These lev-
els decreased after treatment with tiludronate, but there was
no correlation between serum OPG levels and markers of
bone turnover or scintigraphic indices [6]. So far, this is the
only report concerning OPG and treatment of Paget’s dis-
ease with bisphosphonate. Therefore, the aim of this prelim-
inary study was to evaluate the usefulness of monitoring
serum OPG levels to assess the response to neridronate ther-
apy in already treated patients with Paget’s disease of bone.
Patients and methods
Nine patients affected by Paget’s disease of bone (4 men and 5
women; age range, 59-80 years; mean±SD, 71±8.7) were includ-
ed in the study. The diagnosis of Paget’s disease was made by
radiography and bone scintigraphy. Three patients had mono-
stotic and 6 had polyostotic disease. Liver and renal function
tests were normal in all patients. 
The patients had been previously treated with clodronate
(300 mg/day, i.v. for five days) for a mean of 2.7 courses of ther-
apy (range, 1-5), and were all judged to be non-responders. Lack
of response to this therapy was defined as a reduction in serum
alkaline phosphatase (AP) five months after treatment by less
than 50% of the pre-treatment value and still remaining above
the upper limit of the normal range. For this reason, patients
were switched to a single course of neridronate (100 mg/day, i.v.
for two days). The criteria to classify non-responders were in
accordance with previous protocols [3, 7].
Laboratory assessment was carried out before and five
months after neridronate treatment. A blood sample and a 2-hour
morning urine sample were collected from each subject after an
overnight fast. Serum and urine were stored at -20° C until
analysis. We measured: serum OPG (Bio Vendor, Brno, Czech
Republic); serum AP (Roche; Basel, CH); serum osteocalcin;
serum bone isoenzyme of alkaline phosphatase (BAP); and uri-
nary deoxypyridinoline/creatinine excretion (DPD) (Quidel; San
Diego, CA, USA). The intraassay and interassay coefficients of
variation (CV) for each marker were, respectively: OPG, 5.0%
and 4.7%; AP, 2.0% and 3.0%; osteocalcin, 7.8% and 7.0%;
BAP, 5.0% and 5.9%; and DPD, 6.1% and 4.2%.
The upper limits of normal values were those from our nor-
mal laboratory population: OPG (mean±SD), 14.59±3.88 U/L;
AP, 77.95±20.24 U/L; osteocalcin, 6.30±2.45 ng/ml; BAP,
25.24±8.11 U/L; DPD, 4.40±1.20 nmol/mmol.
Before neridronate treatment, quantitative bone scintigraphy
was performed 2 hours after an intravenous injection of 740
MBq (20 mCi) of 99mTc-labeled hydroxymethylene bisphospho-
nate. The scintigraphic disease activity index (SAI) of Pons et al.
[8] was calculated.
All subjects gave written informed consent to the study, and
the principles of the Declaration of Helsinki were followed.
Student’s t test for paired and unpaired data, and Pearson’s
correlation test were used for statistical analysis.
Results
We measured the responses of bone metabolism markers to
neridronate treatment in 9 patients with Paget’s disease of
bone unresponsive to clodronate. Five months after ner-
idronate treatment, we observed significant reductions in
serum levels of AP and BAP (41.9% and 38.8%, respective-
ly) compared to pretreatment values (Table 1). Serum levels
of OPG, before and after treatment, were within normal lev-
els, and the reduction after treatment (5.1%) was not statis-
tically significant. There were no significant changes in
osteocalcin or DPD levels.
SAI values ranged from 13 252 to 11 4028 (mean±SD,
55367±39009) and correlated with OPG levels (Pearson’s
r=0.689; p=0.040). Moreover, we observed significant cor-
relations (p=0.001) between OPG and DPD (r=0.925) and
between BAP and AP (r=0.886).
Table 1 Serum osteoprotegerin (OPG) and markers of bone turnover in 9 patients with Paget’s disease of bone, before and 5 months after
neridronate treatment
Before treatment After treatment
OPG (U/L) 11.01 (3.82) 10.44 (3.76)**
AP (U/L) 1081 (297) 628 (374)**
BAP (U/L) 200.63 (62.46) 122.86 (90.75)**
Osteocalcin (ng/ml) 11.64 (5.81) 11.85 (3.06)**
DPD (nmol DPD/mmol creatinine) 15.41 (9.78) 10.33 (5.13)**
*p<0.02; **p<0.04 vs. before treatment, Student’s t test for paired data
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Discussion
Our data do not confirm previous observations [6],
because serum levels of OPG in these patients were in the
range of normal values. However, one can take into
account that none of the patients in the work of Alvarez et
al. [6] had been treated with bisphosphonates during the
previous two years nor with calcitonin during the previous
year. In our series, no variations of OPG were observed
after neridronate therapy. Also osteocalcin and DPD did
not present significant reductions after treatment; their
values remained slightly above the upper limits of normal,
both before and after therapy. On the contrary, as expect-
ed in Paget’s disease of bone, AP and BAP underwent sta-
tistically significant decreases after neridronate adminis-
tration, even if they did not reach the normal values.
Reduction in serum AP and BAP after bisphosphonate
treatment is still widely used for monitoring the efficacy
of therapy in patients with Paget’s disease of bone [9].
One explanation for the absence of a significant varia-
tion in OPG, osteocalcin and DPD after therapy could be
the limited statistical power of the study due to the small
number of cases. Otherwise, another hypothesis is the low
bone turnover in these patients, who had been previously
repeatedly treated with clodronate, a non-selective first-
generation bisphosphonate. Another consideration is that
OPG determinations were carried out at basal time and
after 5 months. Therefor, we cannot exclude a possible
temporary decrease of serum OPG before the fifth month
after neridronate administration. Nevertheless, the posi-
tive correlation between OPG and SAI may indicate that
OPG is related to disease activity, and the positive corre-
lation with DPD can be explained by a compensatory
inhibitory mechanism of osteoclastic hyperactivity carried
out by OPG.
In conclusion, our preliminary data suggest that OPG
is not useful for assessing activity and response to re-treat-
ment in Paget’s disease of bone, even if it is an important
regulator of bone metabolism. On the contrary, the study
confirms the usefulness of AP and its bone isoenzyme also
in those patients with low bone remodeling due to previ-
ous courses of bisphosphonate treatment. The results of
this preliminary study should be confirmed in studies with
a larger number of cases.
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